These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 15199290)

  • 21. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
    Sprague SM
    Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits.
    Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate.
    Behets GJ; Verberckmoes SC; Oste L; Bervoets AR; Salomé M; Cox AG; Denton J; De Broe ME; D'Haese PC
    Kidney Int; 2005 May; 67(5):1830-6. PubMed ID: 15840030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
    Shigematsu T;
    Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lanthanum: a safe phosphate binder.
    Persy VP; Behets GJ; Bervoets AR; De Broe ME; D'Haese PC
    Semin Dial; 2006; 19(3):195-9. PubMed ID: 16689967
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
    Joy MS; Finn WF;
    Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Evaluation of the Safety, Efficacy and Tolerability of Lanthanum Carbonate in the Management of Hyperphosphatemia in Patients with End-Stage Renal Disease.
    Cernaro V; Calimeri S; Laudani A; Santoro D
    Ther Clin Risk Manag; 2020; 16():871-880. PubMed ID: 32982259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
    Navaneethan SD; Palmer SC; Craig JC; Elder GJ; Strippoli GF
    Am J Kidney Dis; 2009 Oct; 54(4):619-37. PubMed ID: 19692157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease.
    Freemont AJ; Hoyland JA; Denton J;
    Clin Nephrol; 2005 Dec; 64(6):428-37. PubMed ID: 16370155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Introduction to lanthanum carbonate: pharmacology, safety and tolerability].
    Rodríguez Portillo M
    Nefrologia; 2008; 28 Suppl 5():7-10. PubMed ID: 18847413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
    Shigematsu T;
    Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia].
    Laville M
    Nephrol Ther; 2011 Jun; 7(3):154-61. PubMed ID: 21247818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
    Shigematsu T; Ohya M; Negi S; Masumoto AR; Nakashima YM; Iwatani Y; Moribata MK; Yamanaka S; Tatsuta K; Mima T
    Contrib Nephrol; 2015; 185():42-55. PubMed ID: 26023014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lanthanum carbonate: safety data after 10 years.
    Hutchison AJ; Wilson RJ; Garafola S; Copley JB
    Nephrology (Carlton); 2016 Dec; 21(12):987-994. PubMed ID: 27479781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia.
    Shigematsu T; Tokumoto A; Nakaoka A; Arisaka H
    Ther Apher Dial; 2011 Apr; 15(2):176-84. PubMed ID: 21426511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.
    Hutchison AJ; Maes B; Vanwalleghem J; Asmus G; Mohamed E; Schmieder R; Backs W; Jamar R; Vosskühler A
    Nephron Clin Pract; 2006; 102(2):c61-71. PubMed ID: 16224198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical management of hyperphosphatemia.
    Ritz E
    J Nephrol; 2005; 18(3):221-8. PubMed ID: 16013007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats.
    Neven E; Dams G; Postnov A; Chen B; De Clerck N; De Broe ME; D'Haese PC; Persy V
    Nephrol Dial Transplant; 2009 Jun; 24(6):1790-9. PubMed ID: 19144999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blast from the past: the aluminum's ghost on the lanthanum salts.
    Canavese C; Mereu C; Nordio M; Sabbioni E; Aime S
    Curr Med Chem; 2005; 12(14):1631-6. PubMed ID: 16022663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lanthanum carbonate.
    Swainston Harrison T; Scott LJ
    Drugs; 2004; 64(9):985-96; discussion 997-8. PubMed ID: 15101790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.